Identification

Name
Desipramine
Accession Number
DB01151  (APRD00022, DB07682)
Type
Small Molecule
Groups
Approved
Description

Desipramine hydrochloride is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, desipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, desipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Secondary amine TCAs, such as desipramine and nortriptyline, are more potent inhibitors of norepinephrine reuptake than tertiary amine TCAs, such as amitriptyline and doxepine. TCAs also down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine-H1 receptors, α1-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Desipramine exerts less anticholinergic and sedative side effects compared to tertiary amine TCAs, such as amitriptyline and clomipramine. Desipramine may be used to treat depression, neuropathic pain (unlabeled use), agitation and insomnia (unlabeled use) and attention-deficit hyperactivity disorder (unlabeled use).

Structure
Thumb
Synonyms
  • 3-(10,11-DIHYDRO-5H-dibenzo[b,F]azepin-5-yl)-N-methylpropan-1-amine
  • 5-(gamma-Methylaminopropyl)iminodibenzyl
  • 5-(γ-methylaminopropyl)iminodibenzyl
  • Déméthylimipramine
  • Desipramin
  • Desipramina
  • Desipramine
  • Desipraminum
  • Desmethylimipramine
  • DMI
  • Monodemethylimipramine
  • N-(3-methylaminopropyl)iminobibenzyl
  • Norimipramine
Product Ingredients
IngredientUNIICASInChI Key
Desipramine Hydrochloride1Y58DO4MY158-28-6XAEWZDYWZHIUCT-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DesipramineTablet10 mgOralAa Pharma Inc1996-12-31Not applicableCanada
DesipramineTablet100 mgOralAa Pharma Inc1996-12-31Not applicableCanada
DesipramineTablet50 mgOralAa Pharma Inc1996-12-31Not applicableCanada
DesipramineTablet25 mgOralAa Pharma Inc1996-12-31Not applicableCanada
DesipramineTablet75 mgOralAa Pharma Inc1996-12-31Not applicableCanada
Desipramine HydrochlorideTablet, sugar coated100 mg/1OralWinthrop U.S.2014-04-01Not applicableUs
Desipramine HydrochlorideTablet, sugar coated25 mg/1OralWinthrop U.S.2014-04-01Not applicableUs
Desipramine HydrochlorideTablet, sugar coated75 mg/1OralWinthrop U.S.2014-04-01Not applicableUs
Desipramine HydrochlorideTablet, sugar coated150 mg/1OralWinthrop U.S.2014-04-01Not applicableUs
Desipramine HydrochlorideTablet, sugar coated10 mg/1OralWinthrop U.S.2014-04-01Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Desipramine HydrochlorideTablet10 mg/1OralRemedy Repack2011-04-182016-10-13Us
Desipramine HydrochlorideTablet25 mg/1OralHeritage2016-11-01Not applicableUs
Desipramine HydrochlorideTablet, film coated10 mg/1OralCore Pharma, Llc2017-01-20Not applicableUs
Desipramine HydrochlorideTablet, film coated25 mg/1OralRebel Distributors1988-05-24Not applicableUs
Desipramine HydrochlorideTablet, film coated25 mg/1OralAmneal Pharmaceuticals2016-03-21Not applicableUs
Desipramine HydrochlorideTablet50 mg/1OralINDICUS PHARMA LLC2016-08-01Not applicableUs
Desipramine HydrochlorideTablet, film coated100 mg/1OralSandoz1988-06-20Not applicableUs
Desipramine HydrochlorideTablet, film coated10 mg/1OralAvera Mc Kennan Hospital2016-02-15Not applicableUs
Desipramine HydrochlorideTablet150 mg/1OralIngenus Pharmaceuticals Llc2018-01-06Not applicableUs
Desipramine HydrochlorideTablet, film coated10 mg/1OralSandoz1988-05-242016-12-31Us
International/Other Brands
Pertofran (Ciba) / Pertofrane (USV)
Categories
UNII
TG537D343B
CAS number
50-47-5
Weight
Average: 266.3807
Monoisotopic: 266.178298714
Chemical Formula
C18H22N2
InChI Key
HCYAFALTSJYZDH-UHFFFAOYSA-N
InChI
InChI=1S/C18H22N2/c1-19-13-6-14-20-17-9-4-2-7-15(17)11-12-16-8-3-5-10-18(16)20/h2-5,7-10,19H,6,11-14H2,1H3
IUPAC Name
(3-{2-azatricyclo[9.4.0.0³,⁸]pentadeca-1(15),3,5,7,11,13-hexaen-2-yl}propyl)(methyl)amine
SMILES
CNCCCN1C2=CC=CC=C2CCC2=CC=CC=C12

Pharmacology

Indication

For relief of symptoms in various depressive syndromes, especially endogenous depression. It has also been used to manage chronic peripheral neuropathic pain, as a second line agent for the management of anxiety disorders (e.g. panic disorder, generalized anxiety disorder), and as a second or third line agent in the ADHD management.

Structured Indications
Pharmacodynamics

Desipramine, a secondary amine tricyclic antidepressant, is structurally related to both the skeletal muscle relaxant cyclobenzaprine and the thioxanthene antipsychotics such as thiothixene. It is the active metabolite of imipramine, a tertiary amine TCA. The acute effects of desipramine include inhibition of noradrenaline re-uptake at noradrenergic nerve endings and inhibition of serotonin (5-hydroxy tryptamine, 5HT) re-uptake at the serotoninergic nerve endings in the central nervous system. Desipramine exhibits greater noradrenergic re-uptake inhibition compared to the tertiary amine TCA imipramine. In addition to inhibiting neurotransmitter re-uptake, desipramine down-regulates beta-adrenergic receptors in the cerebral cortex and sensitizes serotonergic receptors with chronic use. The overall effect is increased serotonergic transmission. Antidepressant effects are typically observed 2 - 4 weeks following the onset of therapy though some patients may require up to 8 weeks of therapy prior to symptom improvement. Patients experiencing more severe depressive episodes may respond quicker than those with mild depressive symptoms.

Mechanism of action

Desipramine is a tricyclic antidepressant (TCA) that selectively blocks reuptake of norepinephrine (noradrenaline) from the neuronal synapse. It also inhibits serotonin reuptake, but to a lesser extent compared to tertiary amine TCAs such as imipramine. Inhibition of neurotransmitter reuptake increases stimulation of the post-synaptic neuron. Chronic use of desipramine also leads to down-regulation of beta-adrenergic receptors in the cerebral cortex and sensitization of serotonergic receptors. An overall increase in serotonergic transmission likely confers desipramine its antidepressant effects. Desipramine also possesses minor anticholinergic activity, through its affinity for muscarinic receptors. TCAs are believed to act by restoring normal levels of neurotransmitters via synaptic reuptake inhibition and by increasing serotonergic neurotransmission via serotonergic receptor sensitization in the central nervous system.

TargetActionsOrganism
ASodium-dependent noradrenaline transporter
inhibitor
Human
ASodium-dependent serotonin transporter
inhibitor
Human
A5-hydroxytryptamine receptor 2A
antagonist
Human
UBeta-2 adrenergic receptor
antagonist
Human
UBeta-1 adrenergic receptor
other
Human
USphingomyelin phosphodiesterase
inhibitor
Human
NHistamine H1 receptor
antagonist
Human
NAlpha-1 adrenergic receptors
antagonist
Human
NMuscarinic acetylcholine receptor M1
antagonist
Human
NMuscarinic acetylcholine receptor M2
antagonist
Human
NMuscarinic acetylcholine receptor M3
antagonist
Human
NMuscarinic acetylcholine receptor M4
antagonist
Human
NMuscarinic acetylcholine receptor M5
antagonist
Human
U5-hydroxytryptamine receptor 1A
binder
Human
U5-hydroxytryptamine receptor 2C
binder
Human
UD(2) dopamine receptor
binder
Human
UAlpha-2 adrenergic receptors
binder
Human
Absorption

Desipramine hydrochloride is rapidly and almost completely absorbed from the gastrointestinal tract. It undergoes extensive first-pass metabolism. Peak plasma concentrations are attained 4 - 6 hours following oral administration.

Volume of distribution
Not Available
Protein binding

73-92% bound to plasma proteins

Metabolism

Desipramine is extensively metabolized in the liver by CYP2D6 (major) and CYP1A2 (minor) to 2-hydroxydesipramine, an active metabolite. 2-hydroxydesipramine is thought to retain some amine reuptake inhibition and may possess cardiac depressant activity. The 2-hydroxylation metabolic pathway of desipramine is under genetic control.

Route of elimination

Desipramine is metabolized in the liver, and approximately 70% is excreted in the urine.

Half life

7-60+ hours; 70% eliminated renally

Clearance
Not Available
Toxicity

Male mice: LD50 = 290 mg/kg, female rats: LD50 = 320 mg/kg. Antagonism of the histamine H1 and α1 receptors can lead to sedation and hypotension. Antimuscarinic activity confers anticholinergic side effects such as blurred vision, dry mouth, constipation and urine retention may occur. Cardiotoxicity may occur with high doses of desipramine. Cardiovascular side effects in postural hypotension, tachycardia, hypertension, ECG changes and congestive heart failure. Psychotoxic effects include impaired memory and delirium. Induction of hypomanic or manic episodes may occur in patients with a history of bipolar disorder. Withdrawal symptoms include GI disturbances (e.g. nausea, vomiting, abdominal pain, diarrhea), anxiety, insomnia, nervousness, headache and malaise.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Imipramine Action PathwayDrug action
Desipramine Action PathwayDrug action
Imipramine Metabolism PathwayDrug metabolism
Desipramine Metabolism PathwayDrug metabolism
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Cytochrome P450 2D6CYP2D6*4(A;A)A AlleleEffect Directly StudiedPatients with this genotype have reduced metabolism of desipramine.Details
Cytochrome P450 2D6CYP2D6*3Not Available2549delAEffect Directly StudiedThe presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of desipramine.Details
Cytochrome P450 2D6CYP2D6*4Not AvailableA alleleEffect Directly StudiedThe presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of desipramine.Details
Cytochrome P450 2D6CYP2D6*5Not AvailableWhole-gene deletionEffect Directly StudiedThe presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of desipramine.Details
Cytochrome P450 2D6CYP2D6*6Not Available1707delTEffect Directly StudiedThe presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of desipramine.Details
Cytochrome P450 2D6CYP2D6*7Not Available2935A>CEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*8Not Available1758G>TEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*11Not Available883G>CEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*12Not Available124G>AEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*13Not AvailableCYP2D7/2D6 hybrid gene structureEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*14ANot Available1758G>AEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*15Not Available137insT, 137_138insTEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*19Not Available2539_2542delAACTEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*20Not Available1973_1974insGEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*21Not Available2573insCEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*31Not Available-1770G>A / -1584C>G  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*36Not Available100C>T / -1426C>T  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*38Not Available2587_2590delGACTEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*40Not Available1863_1864ins(TTT CGC CCC)2Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*42Not Available3259_3260insGTEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*44Not Available2950G>CEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*47Not Available100C>T / -1426C>T  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*51Not Available-1584C>G / -1235A>G  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*56Not Available3201C>TEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*57Not Available100C>T / 310G>T  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*62Not Available4044C>TEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*68ANot Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*68BNot AvailableSimilar but not identical switch region compared to CYP2D6*68A. Found in tandem arrangement with CYP2D6*4.Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*69Not Available2988G>A / -1426C>T  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*92Not Available1995delCEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*100Not Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*101Not Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*3Not AvailableC alleleEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*5Not AvailableWhole-gene deletionEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*6Not Available1707delTEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*7Not Available2935A>CEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*8Not Available1758G>TEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*11Not Available883G>CEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*12Not Available124G>AEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*13Not AvailableCYP2D7/2D6 hybrid gene structureEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*14ANot Available1758G>AEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*15Not Available137insT, 137_138insTEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*19Not Available2539_2542delAACTEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*20Not Available1973_1974insGEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*21Not Available2573insCEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*31Not Available-1770G>A / -1584C>G  … show all Effect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*36Not Available100C>T / -1426C>T  … show all Effect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*38Not Available2587_2590delGACTEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*40Not Available1863_1864ins(TTT CGC CCC)2Effect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*42Not Available3259_3260insGTEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*44Not Available2950G>CEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*47Not Available100C>T / -1426C>T  … show all Effect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*51Not Available-1584C>G / -1235A>G  … show all Effect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*56Not Available3201C>TEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*57Not Available100C>T / 310G>T  … show all Effect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*62Not Available4044C>TEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*68ANot Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*68BNot AvailableSimilar but not identical switch region compared to CYP2D6*68A. Found in tandem arrangement with CYP2D6*4.Effect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*69Not Available2988G>A / -1426C>T  … show all Effect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*92Not Available1995delCEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*100Not Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*101Not Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*3Not AvailableG alleleEffect Directly StudiedThe presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of desipramine.Details
Cytochrome P450 2D6CYP2D6*4Not Available3877G>AEffect Directly StudiedThe presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of desipramine.Details

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe serum concentration of Desipramine can be increased when it is combined with 1,10-Phenanthroline.Experimental
2,5-Dimethoxy-4-ethylamphetamineDesipramine may increase the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamineDesipramine may increase the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
3,4-DichloroisocoumarinThe serum concentration of Desipramine can be increased when it is combined with 3,4-Dichloroisocoumarin.Experimental
3,4-MethylenedioxyamphetamineDesipramine may increase the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-(2-Aminoethyl)Benzenesulfonyl FluorideThe serum concentration of Desipramine can be increased when it is combined with 4-(2-Aminoethyl)Benzenesulfonyl Fluoride.Experimental
4-Bromo-2,5-dimethoxyamphetamineDesipramine may increase the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
4-MethoxyamphetamineDesipramine may decrease the antihypertensive activities of 4-Methoxyamphetamine.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Desipramine.Experimental
AbirateroneThe serum concentration of Desipramine can be increased when it is combined with Abiraterone.Approved
AcenocoumarolDesipramine may increase the anticoagulant activities of Acenocoumarol.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Desipramine.Approved
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Desipramine.Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Desipramine.Approved
AgmatineDesipramine may decrease the antihypertensive activities of Agmatine.Experimental, Investigational
AjmalineThe metabolism of Ajmaline can be decreased when combined with Desipramine.Approved, Investigational
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Desipramine.Approved, Investigational
AlogliptinThe serum concentration of Desipramine can be increased when it is combined with Alogliptin.Approved
Alpha-1-proteinase inhibitorThe serum concentration of Desipramine can be increased when it is combined with Alpha-1-proteinase inhibitor.Approved
AlprenololThe metabolism of Alprenolol can be decreased when combined with Desipramine.Approved, Withdrawn
AltretamineAltretamine may increase the orthostatic hypotensive activities of Desipramine.Approved
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Desipramine.Approved, Withdrawn
AmiodaroneThe metabolism of Desipramine can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Desipramine.Approved
AmobarbitalThe metabolism of Desipramine can be increased when combined with Amobarbital.Approved, Illicit
AmoxapineThe metabolism of Amoxapine can be decreased when combined with Desipramine.Approved
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Desipramine.Approved, Illicit
AmprenavirThe serum concentration of Desipramine can be increased when it is combined with Amprenavir.Approved
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Desipramine.Approved
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Desipramine.Approved
Antithrombin III humanThe serum concentration of Desipramine can be increased when it is combined with Antithrombin III human.Approved
ApixabanThe serum concentration of Desipramine can be increased when it is combined with Apixaban.Approved
ApomorphineDesipramine may decrease the antihypertensive activities of Apomorphine.Approved, Investigational
ApraclonidineDesipramine may decrease the antihypertensive activities of Apraclonidine.Approved
AprindineThe metabolism of Aprindine can be decreased when combined with Desipramine.Approved
AprotininThe serum concentration of Desipramine can be increased when it is combined with Aprotinin.Approved, Withdrawn
ArbutamineThe risk or severity of adverse effects can be increased when Desipramine is combined with Arbutamine.Approved
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Desipramine.Approved, Investigational
ArgatrobanThe serum concentration of Desipramine can be increased when it is combined with Argatroban.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Desipramine.Approved, Investigational
ArmodafinilThe metabolism of Desipramine can be decreased when combined with Armodafinil.Approved, Investigational
ArtemetherThe metabolism of Artemether can be decreased when combined with Desipramine.Approved
ArtesunateThe serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Desipramine resulting in a loss in efficacy.Approved, Investigational
AstemizoleThe metabolism of Astemizole can be decreased when combined with Desipramine.Approved, Withdrawn
AsunaprevirThe serum concentration of Desipramine can be increased when it is combined with Asunaprevir.Approved, Investigational
AtazanavirThe serum concentration of Desipramine can be increased when it is combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Desipramine can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Desipramine is combined with Atorvastatin.Approved
AzelastineThe metabolism of Azelastine can be decreased when combined with Desipramine.Approved
AzithromycinThe metabolism of Desipramine can be decreased when combined with Azithromycin.Approved
BambuterolThe risk or severity of adverse effects can be increased when Desipramine is combined with Bambuterol.Approved, Investigational
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Desipramine.Investigational
BarbexacloneThe metabolism of Desipramine can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Desipramine can be increased when combined with Barbital.Illicit
BatimastatThe serum concentration of Desipramine can be increased when it is combined with Batimastat.Experimental
BenazeprilThe serum concentration of Desipramine can be increased when it is combined with Benazepril.Approved, Investigational
BenzamidineThe serum concentration of Desipramine can be increased when it is combined with Benzamidine.Experimental
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Desipramine.Approved
BenzphetamineDesipramine may decrease the antihypertensive activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Desipramine.Approved
BepridilThe metabolism of Bepridil can be decreased when combined with Desipramine.Approved, Withdrawn
BetaxololThe metabolism of Betaxolol can be decreased when combined with Desipramine.Approved
BethanidineDesipramine may decrease the antihypertensive activities of Bethanidine.Approved
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Desipramine.Approved
BivalirudinThe serum concentration of Desipramine can be increased when it is combined with Bivalirudin.Approved, Investigational
BoceprevirThe serum concentration of Desipramine can be increased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Desipramine can be decreased when combined with Bortezomib.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Desipramine.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Desipramine.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Desipramine.Approved
BrivaracetamThe metabolism of Brivaracetam can be decreased when combined with Desipramine.Approved, Investigational
BrofaromineBrofaromine may increase the serotonergic activities of Desipramine.Experimental
BromocriptineDesipramine may decrease the antihypertensive activities of Bromocriptine.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Desipramine.Approved
BufuralolThe metabolism of Bufuralol can be decreased when combined with Desipramine.Experimental, Investigational
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Desipramine.Approved, Investigational
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Desipramine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Desipramine can be decreased when combined with Bupropion.Approved
BuspironeThe metabolism of Buspirone can be decreased when combined with Desipramine.Approved, Investigational
CaffeineThe metabolism of Desipramine can be decreased when combined with Caffeine.Approved
CamostatThe serum concentration of Desipramine can be increased when it is combined with Camostat.Experimental
CandoxatrilThe serum concentration of Desipramine can be increased when it is combined with Candoxatril.Experimental
CandoxatrilatThe serum concentration of Desipramine can be increased when it is combined with Candoxatrilat.Experimental
CaptoprilThe serum concentration of Desipramine can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Desipramine can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Desipramine.Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Desipramine.Approved
CarteololThe metabolism of Carteolol can be decreased when combined with Desipramine.Approved
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Desipramine.Approved, Investigational
CelecoxibThe metabolism of Desipramine can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololThe risk or severity of adverse effects can be increased when Desipramine is combined with Celiprolol.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Desipramine.Approved, Vet Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Desipramine.Withdrawn
CevimelineThe metabolism of Cevimeline can be decreased when combined with Desipramine.Approved
ChloramphenicolThe metabolism of Desipramine can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Desipramine.Approved, Illicit
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Desipramine.Approved, Vet Approved
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Desipramine.Approved
ChlorphentermineDesipramine may increase the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineThe metabolism of Desipramine can be decreased when combined with Chlorpromazine.Approved, Vet Approved
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Desipramine.Approved
CholecalciferolThe metabolism of Desipramine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholesterolThe serum concentration of Desipramine can be increased when it is combined with Cholesterol.Experimental, Investigational
ChymostatinThe serum concentration of Desipramine can be increased when it is combined with Chymostatin.Experimental
CilastatinThe serum concentration of Desipramine can be increased when it is combined with Cilastatin.Approved
CilazaprilThe serum concentration of Desipramine can be increased when it is combined with Cilazapril.Approved
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Desipramine.Approved
CimetidineThe metabolism of Desipramine can be decreased when combined with Cimetidine.Approved
CinacalcetThe serum concentration of Desipramine can be increased when it is combined with Cinacalcet.Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Desipramine.Approved, Investigational
CirazolineDesipramine may increase the vasopressor activities of Cirazoline.Experimental
CisaprideThe metabolism of Cisapride can be decreased when combined with Desipramine.Approved, Investigational, Withdrawn
CitalopramThe risk or severity of adverse effects can be increased when Desipramine is combined with Citalopram.Approved
ClemastineThe metabolism of Desipramine can be decreased when combined with Clemastine.Approved
ClenbuterolThe risk or severity of adverse effects can be increased when Desipramine is combined with Clenbuterol.Approved, Investigational, Vet Approved
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Desipramine.Approved
ClobazamThe metabolism of Desipramine can be decreased when combined with Clobazam.Approved, Illicit
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Desipramine.Investigational
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Desipramine.Approved, Vet Approved
ClonidineDesipramine may decrease the antihypertensive activities of Clonidine.Approved
ClopidogrelThe metabolism of Clopidogrel can be decreased when combined with Desipramine.Approved
ClorindioneDesipramine may increase the anticoagulant activities of Clorindione.Experimental
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Desipramine.Approved, Illicit
ClotrimazoleThe metabolism of Desipramine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Clozapine can be decreased when combined with Desipramine.Approved
CobicistatThe serum concentration of Desipramine can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Desipramine can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Desipramine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Desipramine.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Desipramine.Approved
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Desipramine.Approved, Investigational
Cyproterone acetateThe serum concentration of Desipramine can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Desipramine.Approved
DabrafenibThe serum concentration of Desipramine can be decreased when it is combined with Dabrafenib.Approved
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Desipramine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Desipramine.Investigational
DarexabanThe serum concentration of Desipramine can be increased when it is combined with Darexaban.Investigational
DarifenacinThe metabolism of Desipramine can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Desipramine can be increased when it is combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Desipramine.Approved
DebrisoquinThe metabolism of Debrisoquin can be decreased when combined with Desipramine.Approved, Investigational
DeferasiroxThe serum concentration of Desipramine can be increased when it is combined with Deferasirox.Approved, Investigational
DelanzomibThe serum concentration of Desipramine can be increased when it is combined with Delanzomib.Investigational
DelaprilThe serum concentration of Desipramine can be increased when it is combined with Delapril.Experimental
DelavirdineThe metabolism of Desipramine can be decreased when combined with Delavirdine.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Desipramine is combined with Desmopressin.Approved
DeutetrabenazineThe metabolism of Deutetrabenazine can be decreased when combined with Desipramine.Approved, Investigational
Dexchlorpheniramine maleateThe metabolism of Dexchlorpheniramine maleate can be decreased when combined with Desipramine.Approved
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Desipramine.Approved, Illicit, Investigational, Withdrawn
DexmedetomidineDesipramine may decrease the antihypertensive activities of Dexmedetomidine.Approved, Vet Approved
DexmethylphenidateThe risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Desipramine.Approved
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Desipramine.Approved, Illicit
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Desipramine.Approved
DiazepamThe metabolism of Diazepam can be decreased when combined with Desipramine.Approved, Illicit, Vet Approved
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Desipramine.Approved, Vet Approved
DicoumarolDesipramine may increase the anticoagulant activities of Dicoumarol.Approved
DiethylpropionDesipramine may increase the stimulatory activities of Diethylpropion.Approved, Illicit
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Desipramine.Approved, Illicit
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Desipramine.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Desipramine.Approved, Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Desipramine.Experimental
DihydroergotamineDesipramine may decrease the antihypertensive activities of Dihydroergotamine.Approved
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Desipramine.Approved
DiphenadioneDesipramine may increase the anticoagulant activities of Diphenadione.Experimental
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Desipramine.Approved
DipivefrinDesipramine may decrease the antihypertensive activities of Dipivefrin.Approved
DobutamineThe risk or severity of adverse effects can be increased when Desipramine is combined with Dobutamine.Approved
DolasetronThe metabolism of Dolasetron can be decreased when combined with Desipramine.Approved
DomperidoneThe metabolism of Domperidone can be decreased when combined with Desipramine.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Desipramine.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Desipramine.Approved
DosulepinThe metabolism of Desipramine can be decreased when combined with Dosulepin.Approved
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Desipramine.Approved
DoxepinThe metabolism of Doxepin can be decreased when combined with Desipramine.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Desipramine.Approved, Investigational
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Desipramine.Approved, Investigational
DronedaroneThe metabolism of Dronedarone can be decreased when combined with Desipramine.Approved
DroxidopaDesipramine may decrease the antihypertensive activities of Droxidopa.Approved, Investigational
DuloxetineDuloxetine may increase the serotonergic activities of Desipramine.Approved
EcabetThe serum concentration of Desipramine can be increased when it is combined with Ecabet.Approved, Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Desipramine.Approved
EfavirenzThe metabolism of Desipramine can be decreased when combined with Efavirenz.Approved, Investigational
ElafinThe serum concentration of Desipramine can be increased when it is combined with Elafin.Investigational
EletriptanThe metabolism of Eletriptan can be decreased when combined with Desipramine.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Desipramine.Approved
EnalaprilThe serum concentration of Desipramine can be increased when it is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe serum concentration of Desipramine can be increased when it is combined with Enalaprilat.Approved
EnalkirenThe serum concentration of Desipramine can be increased when it is combined with Enalkiren.Experimental
EnasidenibThe metabolism of Enasidenib can be decreased when combined with Desipramine.Approved
EncainideThe metabolism of Encainide can be decreased when combined with Desipramine.Approved, Investigational, Withdrawn
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Desipramine.Investigational
EphedraDesipramine may decrease the antihypertensive activities of Ephedra.Approved, Nutraceutical, Withdrawn
Epigallocatechin GallateThe serum concentration of Desipramine can be increased when it is combined with Epigallocatechin Gallate.Investigational
EpinastineThe metabolism of Epinastine can be decreased when combined with Desipramine.Approved, Investigational
EpinephrineDesipramine may decrease the antihypertensive activities of Epinephrine.Approved, Vet Approved
ErgotamineDesipramine may decrease the antihypertensive activities of Ergotamine.Approved
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Desipramine.Approved, Investigational
ErythromycinThe metabolism of Erythromycin can be decreased when combined with Desipramine.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Desipramine is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe metabolism of Desipramine can be decreased when combined with Eslicarbazepine acetate.Approved
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Desipramine.Investigational
EsomeprazoleThe metabolism of Desipramine can be decreased when combined with Esomeprazole.Approved, Investigational
EstroneThe metabolism of Estrone can be decreased when combined with Desipramine.Approved
Ethyl biscoumacetateDesipramine may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Desipramine.Approved, Illicit
EtomidateDesipramine may decrease the antihypertensive activities of Etomidate.Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Desipramine.Approved, Investigational
EtravirineThe metabolism of Desipramine can be decreased when combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Desipramine.Approved
FaldaprevirThe serum concentration of Desipramine can be increased when it is combined with Faldaprevir.Investigational
FenoterolThe risk or severity of adverse effects can be increased when Desipramine is combined with Fenoterol.Approved, Investigational
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Desipramine.Approved
FingolimodThe metabolism of Fingolimod can be decreased when combined with Desipramine.Approved, Investigational
FlecainideThe metabolism of Flecainide can be decreased when combined with Desipramine.Approved, Withdrawn
FluconazoleThe metabolism of Desipramine can be decreased when combined with Fluconazole.Approved
FluindioneDesipramine may increase the anticoagulant activities of Fluindione.Investigational
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Desipramine.Approved
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Desipramine.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Desipramine.Approved, Vet Approved
FluphenazineThe metabolism of Fluphenazine can be decreased when combined with Desipramine.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Desipramine.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Desipramine.Approved, Investigational
FormoterolThe metabolism of Formoterol can be decreased when combined with Desipramine.Approved, Investigational
FosamprenavirThe serum concentration of Desipramine can be increased when it is combined with Fosamprenavir.Approved
FosinoprilThe serum concentration of Desipramine can be increased when it is combined with Fosinopril.Approved
FosphenytoinThe metabolism of Desipramine can be increased when combined with Fosphenytoin.Approved
FurazolidoneFurazolidone may increase the serotonergic activities of Desipramine.Approved, Investigational, Vet Approved
GabexateThe serum concentration of Desipramine can be increased when it is combined with Gabexate.Investigational
GalantamineThe metabolism of Galantamine can be decreased when combined with Desipramine.Approved
GefitinibThe metabolism of Gefitinib can be decreased when combined with Desipramine.Approved, Investigational
GeldanamycinThe serum concentration of Desipramine can be increased when it is combined with Geldanamycin.Experimental, Investigational
GemfibrozilThe metabolism of Desipramine can be decreased when combined with Gemfibrozil.Approved
GepefrineDesipramine may increase the stimulatory activities of Gepefrine.Experimental
GM6001The serum concentration of Desipramine can be increased when it is combined with GM6001.Experimental
GranisetronThe metabolism of Granisetron can be decreased when combined with Desipramine.Approved, Investigational
GuanabenzDesipramine may decrease the antihypertensive activities of Guanabenz.Approved, Investigational
GuanfacineDesipramine may decrease the antihypertensive activities of Guanfacine.Approved, Investigational
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Desipramine.Approved
HaloperidolThe metabolism of Desipramine can be decreased when combined with Haloperidol.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Desipramine.Approved, Vet Approved
HarmalineHarmaline may increase the serotonergic activities of Desipramine.Experimental
HexobarbitalThe metabolism of Desipramine can be increased when combined with Hexobarbital.Approved
HydrocodoneThe metabolism of Hydrocodone can be decreased when combined with Desipramine.Approved, Illicit
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Desipramine.Approved, Illicit
HydroxyamphetamineDesipramine may increase the stimulatory activities of Hydroxyamphetamine.Approved
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Desipramine.Approved
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Desipramine.Approved
IdraparinuxThe serum concentration of Desipramine can be increased when it is combined with Idraparinux.Investigational
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Desipramine.Approved
IloperidoneThe metabolism of Iloperidone can be decreased when combined with Desipramine.Approved
ImatinibThe metabolism of Imatinib can be decreased when combined with Desipramine.Approved
ImidaprilThe serum concentration of Desipramine can be increased when it is combined with Imidapril.Investigational
ImipramineThe metabolism of Imipramine can be decreased when combined with Desipramine.Approved
IndacaterolThe risk or severity of adverse effects can be increased when Desipramine is combined with Indacaterol.Approved
IndinavirThe serum concentration of Desipramine can be increased when it is combined with Indinavir.Approved
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Desipramine.Approved, Investigational
Iofetamine I-123Desipramine may increase the stimulatory activities of Iofetamine I-123.Approved
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Desipramine.Approved
IproniazidIproniazid may increase the serotonergic activities of Desipramine.Withdrawn
IrinotecanThe metabolism of Irinotecan can be decreased when combined with Desipramine.Approved, Investigational
IsoetarineThe risk or severity of adverse effects can be increased when Desipramine is combined with Isoetarine.Approved
IsofluraneThe metabolism of Isoflurane can be decreased when combined with Desipramine.Approved, Vet Approved
IsoflurophateThe serum concentration of Desipramine can be increased when it is combined with Isoflurophate.Approved, Investigational, Withdrawn
IsoniazidThe metabolism of Desipramine can be decreased when combined with Isoniazid.Approved
IsoprenalineThe risk or severity of adverse effects can be increased when Desipramine is combined with Isoprenaline.Approved
IxazomibThe serum concentration of Desipramine can be increased when it is combined with Ixazomib.Approved
KetamineThe metabolism of Ketamine can be decreased when combined with Desipramine.Approved, Vet Approved
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Desipramine.Approved, Investigational
KetoconazoleThe metabolism of Desipramine can be decreased when combined with Ketoconazole.Approved, Investigational
L-TryptophanL-Tryptophan may increase the serotonergic activities of Desipramine.Approved, Nutraceutical, Withdrawn
LabetalolThe metabolism of Labetalol can be decreased when combined with Desipramine.Approved
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Desipramine.Approved
LepirudinThe serum concentration of Desipramine can be increased when it is combined with Lepirudin.Approved
LetaxabanThe serum concentration of Desipramine can be increased when it is combined with Letaxaban.Investigational
LetermovirThe metabolism of Letermovir can be decreased when combined with Desipramine.Approved
LevodopaThe metabolism of Levodopa can be decreased when combined with Desipramine.Approved
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Desipramine.Approved
LevonordefrinDesipramine may decrease the antihypertensive activities of Levonordefrin.Approved
LevosalbutamolThe risk or severity of adverse effects can be increased when Desipramine is combined with Levosalbutamol.Approved
LidocaineThe metabolism of Desipramine can be decreased when combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Desipramine can be increased when it is combined with Linagliptin.Approved
LinezolidLinezolid may increase the serotonergic activities of Desipramine.Approved, Investigational
LisdexamfetamineDesipramine may increase the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LisinoprilThe serum concentration of Desipramine can be increased when it is combined with Lisinopril.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Desipramine.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Desipramine.Approved
LobeglitazoneThe metabolism of Desipramine can be decreased when combined with Lobeglitazone.Approved, Investigational
LofexidineDesipramine may decrease the antihypertensive activities of Lofexidine.Approved, Investigational
LomustineThe metabolism of Lomustine can be decreased when combined with Desipramine.Approved
LoperamideThe metabolism of Loperamide can be decreased when combined with Desipramine.Approved
LopinavirThe metabolism of Desipramine can be decreased when combined with Lopinavir.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Desipramine.Approved
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Desipramine.Approved
LorpiprazoleThe serum concentration of Desipramine can be increased when it is combined with Lorpiprazole.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Desipramine.Approved, Investigational
LuliconazoleThe serum concentration of Desipramine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Desipramine can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Desipramine can be decreased when combined with Lumefantrine.Approved
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Desipramine.Illicit, Investigational, Withdrawn
MalathionThe metabolism of Malathion can be decreased when combined with Desipramine.Approved, Investigational
ManidipineThe metabolism of Desipramine can be decreased when combined with Manidipine.Approved, Investigational
MaprotilineThe metabolism of Maprotiline can be decreased when combined with Desipramine.Approved
MelagatranThe serum concentration of Desipramine can be increased when it is combined with Melagatran.Experimental
MephedroneDesipramine may increase the stimulatory activities of Mephedrone.Investigational
MephentermineDesipramine may increase the vasopressor activities of Mephentermine.Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Desipramine.Investigational, Withdrawn
MequitazineThe metabolism of Mequitazine can be decreased when combined with Desipramine.Approved
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Desipramine.Approved, Investigational
MetaraminolDesipramine may increase the vasopressor activities of Metaraminol.Approved, Investigational
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Desipramine.Experimental
MethadoneThe metabolism of Methadone can be decreased when combined with Desipramine.Approved
MethamphetamineDesipramine may decrease the antihypertensive activities of Methamphetamine.Approved, Illicit
MethohexitalThe metabolism of Desipramine can be increased when combined with Methohexital.Approved
MethotrimeprazineThe metabolism of Desipramine can be decreased when combined with Methotrimeprazine.Approved
MethoxamineDesipramine may increase the vasopressor activities of Methoxamine.Approved, Investigational
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Desipramine.Approved, Investigational, Vet Approved
MethoxyphenamineDesipramine may increase the stimulatory activities of Methoxyphenamine.Experimental
Methylene blueDesipramine may increase the serotonergic activities of Methylene blue.Approved, Investigational
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Desipramine.Approved
MethylphenidateThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Desipramine.Approved, Investigational
MethylphenobarbitalThe metabolism of Desipramine can be increased when combined with Methylphenobarbital.Approved
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Desipramine.Approved
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Desipramine.Approved, Illicit, Withdrawn
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Desipramine.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Desipramine.Approved, Investigational
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Desipramine.Approved, Investigational
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Desipramine.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Desipramine.Experimental
MexiletineThe metabolism of Desipramine can be decreased when combined with Mexiletine.Approved
MianserinThe metabolism of Mianserin can be decreased when combined with Desipramine.Approved, Investigational
MidazolamThe metabolism of Midazolam can be decreased when combined with Desipramine.Approved, Illicit
MidodrineDesipramine may increase the vasopressor activities of Midodrine.Approved
MidomafetamineDesipramine may increase the stimulatory activities of Midomafetamine.Experimental, Illicit, Investigational
MidostaurinThe metabolism of Desipramine can be decreased when combined with Midostaurin.Approved
MinaprineThe metabolism of Minaprine can be decreased when combined with Desipramine.Approved
MirabegronThe serum concentration of Desipramine can be increased when it is combined with Mirabegron.Approved
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Desipramine.Approved
MMDADesipramine may increase the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Desipramine.Approved
ModafinilThe metabolism of Desipramine can be decreased when combined with Modafinil.Approved, Investigational
MoexiprilThe serum concentration of Desipramine can be increased when it is combined with Moexipril.Approved
MorphineThe metabolism of Morphine can be decreased when combined with Desipramine.Approved, Investigational
MoxonidineThe therapeutic efficacy of Moxonidine can be decreased when used in combination with Desipramine.Approved, Investigational
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Desipramine can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.Experimental
NafamostatThe serum concentration of Desipramine can be increased when it is combined with Nafamostat.Approved, Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Desipramine.Approved
NaphazolineDesipramine may decrease the antihypertensive activities of Naphazoline.Approved
NateglinideThe metabolism of Nateglinide can be decreased when combined with Desipramine.Approved, Investigational
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Desipramine.Approved, Investigational
NefazodoneThe metabolism of Nefazodone can be decreased when combined with Desipramine.Approved, Withdrawn
NelfinavirThe serum concentration of Desipramine can be increased when it is combined with Nelfinavir.Approved
NetupitantThe metabolism of Netupitant can be decreased when combined with Desipramine.Approved
NevirapineThe metabolism of Desipramine can be decreased when combined with Nevirapine.Approved
NialamideNialamide may increase the serotonergic activities of Desipramine.Withdrawn
NicardipineThe metabolism of Nicardipine can be decreased when combined with Desipramine.Approved
NicergolineThe metabolism of Nicergoline can be decreased when combined with Desipramine.Approved, Investigational
NicorandilDesipramine may increase the hypotensive activities of Nicorandil.Approved, Investigational
NicotineThe metabolism of Nicotine can be decreased when combined with Desipramine.Approved
NifedipineThe metabolism of Nifedipine can be decreased when combined with Desipramine.Approved
NilotinibThe metabolism of Desipramine can be decreased when combined with Nilotinib.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Desipramine.Approved
NitroaspirinThe serum concentration of Desipramine can be increased when it is combined with Nitroaspirin.Investigational
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Desipramine.Approved, Investigational, Vet Approved
NorepinephrineDesipramine may decrease the antihypertensive activities of Norepinephrine.Approved
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Desipramine.Approved
OlanzapineThe metabolism of Olanzapine can be decreased when combined with Desipramine.Approved, Investigational
OlodaterolThe risk or severity of adverse effects can be increased when Desipramine is combined with Olodaterol.Approved
OmapatrilatThe serum concentration of Desipramine can be increased when it is combined with Omapatrilat.Investigational
OmeprazoleThe metabolism of Desipramine can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronThe metabolism of Ondansetron can be decreased when combined with Desipramine.Approved
OrciprenalineThe risk or severity of adverse effects can be increased when Desipramine is combined with Orciprenaline.Approved
OsimertinibThe serum concentration of Desipramine can be decreased when it is combined with Osimertinib.Approved
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Desipramine.Approved
OtamixabanThe serum concentration of Desipramine can be increased when it is combined with Otamixaban.Investigational
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Desipramine.Approved, Illicit, Investigational
OxymetazolineDesipramine may decrease the antihypertensive activities of Oxymetazoline.Approved
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Desipramine.Approved, Investigational, Vet Approved
PaliperidoneDesipramine may decrease the antihypertensive activities of Paliperidone.Approved
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Desipramine.Approved, Investigational
PanobinostatThe serum concentration of Desipramine can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe metabolism of Desipramine can be decreased when combined with Pantoprazole.Approved
PargylinePargyline may increase the serotonergic activities of Desipramine.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Desipramine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Desipramine.Approved
Peginterferon alfa-2bThe serum concentration of Desipramine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PentamidineThe metabolism of Pentamidine can be decreased when combined with Desipramine.Approved
PentobarbitalThe metabolism of Desipramine can be increased when combined with Pentobarbital.Approved, Vet Approved
PergolideDesipramine may decrease the antihypertensive activities of Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Desipramine.Approved, Investigational
PerindoprilThe serum concentration of Desipramine can be increased when it is combined with Perindopril.Approved
PermethrinThe metabolism of Permethrin can be decreased when combined with Desipramine.Approved, Investigational
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Desipramine.Approved
PethidineThe metabolism of Pethidine can be decreased when combined with Desipramine.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Desipramine.Withdrawn
PhenforminThe metabolism of Phenformin can be decreased when combined with Desipramine.Approved, Investigational, Withdrawn
PhenindioneDesipramine may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenobarbitalThe metabolism of Desipramine can be increased when combined with Phenobarbital.Approved
PhenprocoumonDesipramine may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhentermineDesipramine may increase the stimulatory activities of Phentermine.Approved, Illicit
PhenylephrineDesipramine may increase the vasopressor activities of Phenylephrine.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Desipramine is combined with Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe metabolism of Desipramine can be increased when combined with Phenytoin.Approved, Vet Approved
PhosphoramidonThe serum concentration of Desipramine can be increased when it is combined with Phosphoramidon.Experimental
PindololThe metabolism of Pindolol can be decreased when combined with Desipramine.Approved
PiperazineThe metabolism of Piperazine can be decreased when combined with Desipramine.Approved, Vet Approved
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Desipramine.Approved, Investigational
PirbuterolThe risk or severity of adverse effects can be increased when Desipramine is combined with Pirbuterol.Approved
PirlindolePirlindole may increase the serotonergic activities of Desipramine.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Desipramine.Approved
PonatinibThe metabolism of Ponatinib can be decreased when combined with Desipramine.Approved
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Desipramine.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Desipramine.Approved
PrimidoneThe metabolism of Desipramine can be increased when combined with Primidone.Approved, Vet Approved
PrinomastatThe serum concentration of Desipramine can be increased when it is combined with Prinomastat.Investigational
ProcainamideThe metabolism of Procainamide can be decreased when combined with Desipramine.Approved
ProcaterolThe risk or severity of adverse effects can be increased when Desipramine is combined with Procaterol.Approved, Investigational
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Desipramine.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Desipramine.Approved, Vet Approved
PromazineThe metabolism of Desipramine can be decreased when combined with Promazine.Approved, Vet Approved
PromethazineThe metabolism of Promethazine can be decreased when combined with Desipramine.Approved
PropafenoneThe serum concentration of Desipramine can be increased when it is combined with Propafenone.Approved
PropofolThe metabolism of Propofol can be decreased when combined with Desipramine.Approved, Investigational, Vet Approved
PropranololThe metabolism of Propranolol can be decreased when combined with Desipramine.Approved, Investigational
ProtriptylineThe metabolism of Protriptyline can be decreased when combined with Desipramine.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Desipramine.Approved
PseudoephedrineDesipramine may decrease the antihypertensive activities of Pseudoephedrine.Approved
QuetiapineThe metabolism of Quetiapine can be decreased when combined with Desipramine.Approved
QuinaprilThe serum concentration of Desipramine can be increased when it is combined with Quinapril.Approved, Investigational
QuinidineDesipramine may increase the QTc-prolonging activities of Quinidine.Approved
QuinineThe metabolism of Quinine can be decreased when combined with Desipramine.Approved
RacecadotrilThe serum concentration of Desipramine can be increased when it is combined with Racecadotril.Investigational
RamiprilThe serum concentration of Desipramine can be increased when it is combined with Ramipril.Approved
RanitidineThe metabolism of Ranitidine can be decreased when combined with Desipramine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Desipramine.Approved, Investigational
RemikirenThe serum concentration of Desipramine can be increased when it is combined with Remikiren.Approved
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Desipramine.Approved, Withdrawn
RepinotanThe metabolism of Repinotan can be decreased when combined with Desipramine.Investigational
RifampicinThe metabolism of Desipramine can be increased when combined with Rifampicin.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Desipramine.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be increased when it is combined with Desipramine.Approved
RisperidoneDesipramine may decrease the antihypertensive activities of Risperidone.Approved, Investigational
RitobegronDesipramine may increase the stimulatory activities of Ritobegron.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Desipramine is combined with Ritodrine.Approved, Investigational
RitonavirThe metabolism of Desipramine can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Desipramine can be increased when it is combined with Rivaroxaban.Approved
RolapitantThe metabolism of Desipramine can be decreased when combined with Rolapitant.Approved
RomidepsinThe metabolism of Romidepsin can be decreased when combined with Desipramine.Approved, Investigational
RopiniroleThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Desipramine.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Desipramine.Approved
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Desipramine.Approved
RotigotineThe metabolism of Rotigotine can be decreased when combined with Desipramine.Approved
RucaparibThe metabolism of Rucaparib can be decreased when combined with Desipramine.Approved, Investigational
RupatadineThe metabolism of Rupatadine can be decreased when combined with Desipramine.Approved
S-3304The serum concentration of Desipramine can be increased when it is combined with S-3304.Investigational
SalbutamolThe risk or severity of adverse effects can be increased when Desipramine is combined with Salbutamol.Approved, Vet Approved
SalmeterolThe risk or severity of adverse effects can be increased when Desipramine is combined with Salmeterol.Approved
SaquinavirThe serum concentration of Desipramine can be increased when it is combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Desipramine can be increased when it is combined with Saxagliptin.Approved
SecobarbitalThe metabolism of Desipramine can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe metabolism of Selegiline can be decreased when combined with Desipramine.Approved, Investigational, Vet Approved
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Desipramine.Approved
SertindoleThe metabolism of Sertindole can be decreased when combined with Desipramine.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Desipramine.Approved
SevofluraneThe metabolism of Sevoflurane can be decreased when combined with Desipramine.Approved, Vet Approved
SildenafilThe metabolism of Sildenafil can be decreased when combined with Desipramine.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Desipramine.Approved
SimeprevirThe serum concentration of Desipramine can be increased when it is combined with Simeprevir.Approved
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Desipramine.Approved
SitagliptinThe serum concentration of Desipramine can be increased when it is combined with Sitagliptin.Approved, Investigational
SivelestatThe serum concentration of Desipramine can be increased when it is combined with Sivelestat.Investigational
Sodium phosphateThe risk or severity of adverse effects can be increased when Desipramine is combined with Sodium phosphate.Approved
SorafenibThe metabolism of Sorafenib can be decreased when combined with Desipramine.Approved, Investigational
SparteineThe metabolism of Sparteine can be decreased when combined with Desipramine.Experimental
SpiraprilThe serum concentration of Desipramine can be increased when it is combined with Spirapril.Approved
St. John's WortThe metabolism of Desipramine can be increased when combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe metabolism of Desipramine can be decreased when combined with Stiripentol.Approved
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Desipramine resulting in a loss in efficacy.Approved
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Desipramine.Approved, Investigational
TapentadolThe metabolism of Tapentadol can be decreased when combined with Desipramine.Approved
TegaserodThe metabolism of Tegaserod can be decreased when combined with Desipramine.Investigational, Withdrawn
TelaprevirThe serum concentration of Desipramine can be increased when it is combined with Telaprevir.Approved, Withdrawn
TemazepamThe metabolism of Temazepam can be decreased when combined with Desipramine.Approved
TemocaprilThe serum concentration of Desipramine can be increased when it is combined with Temocapril.Experimental, Investigational
Tenofovir disoproxilThe metabolism of Desipramine can be decreased when combined with Tenofovir disoproxil.Approved, Investigational
TerbinafineThe metabolism of Desipramine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineThe risk or severity of adverse effects can be increased when Desipramine is combined with Terbutaline.Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Desipramine.Withdrawn
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Desipramine.Experimental
TeriflunomideThe serum concentration of Desipramine can be decreased when it is combined with Teriflunomide.Approved
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Desipramine.Investigational
TestosteroneThe metabolism of Testosterone can be decreased when combined with Desipramine.Approved, Investigational
Testosterone cypionateThe metabolism of Testosterone Cypionate can be decreased when combined with Desipramine.Approved
Testosterone enanthateThe metabolism of Testosterone Enanthate can be decreased when combined with Desipramine.Approved
Testosterone undecanoateThe metabolism of Testosterone Undecanoate can be decreased when combined with Desipramine.Approved, Investigational
TetrabenazineThe metabolism of Tetrabenazine can be decreased when combined with Desipramine.Approved
TheophyllineThe metabolism of Desipramine can be decreased when combined with Theophylline.Approved
ThiamylalThe metabolism of Desipramine can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Desipramine can be increased when combined with Thiopental.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Desipramine.Approved, Withdrawn
ThiorphanThe serum concentration of Desipramine can be increased when it is combined with Thiorphan.Experimental
TiclopidineThe metabolism of Desipramine can be decreased when combined with Ticlopidine.Approved
TimololThe metabolism of Timolol can be decreased when combined with Desipramine.Approved
TioclomarolDesipramine may increase the anticoagulant activities of Tioclomarol.Experimental
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Desipramine.Approved
TipranavirThe metabolism of Desipramine can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineDesipramine may decrease the antihypertensive activities of Tizanidine.Approved
ToloxatoneToloxatone may increase the serotonergic activities of Desipramine.Approved
TolterodineThe metabolism of Tolterodine can be decreased when combined with Desipramine.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Desipramine.Approved
TopiramateThe metabolism of Desipramine can be decreased when combined with Topiramate.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Desipramine.Approved, Investigational
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Desipramine.Approved, Investigational
TramadolDesipramine may increase the neuroexcitatory activities of Tramadol.Approved, Investigational
TrandolaprilThe serum concentration of Desipramine can be increased when it is combined with Trandolapril.Approved
TranylcypromineThe metabolism of Desipramine can be decreased when combined with Tranylcypromine.Approved
TrazodoneThe metabolism of Trazodone can be decreased when combined with Desipramine.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be decreased when combined with Desipramine.Approved, Investigational, Nutraceutical
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Desipramine.Approved
UbenimexThe serum concentration of Desipramine can be increased when it is combined with Ubenimex.Experimental, Investigational
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Desipramine.Approved, Investigational, Nutraceutical
UlinastatinThe serum concentration of Desipramine can be increased when it is combined with Ulinastatin.Investigational
UmeclidiniumThe metabolism of Umeclidinium can be decreased when combined with Desipramine.Approved
ValbenazineThe metabolism of Valbenazine can be decreased when combined with Desipramine.Approved, Investigational
Valproic AcidThe serum concentration of Desipramine can be increased when it is combined with Valproic Acid.Approved, Investigational
VelpatasvirThe metabolism of Velpatasvir can be decreased when combined with Desipramine.Approved
VemurafenibThe serum concentration of Desipramine can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe metabolism of Desipramine can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Verapamil can be decreased when combined with Desipramine.Approved
VernakalantThe metabolism of Vernakalant can be decreased when combined with Desipramine.Approved, Investigational
VilanterolThe risk or severity of adverse effects can be increased when Desipramine is combined with Vilanterol.Approved
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Desipramine.Approved
VildagliptinThe serum concentration of Desipramine can be increased when it is combined with Vildagliptin.Approved, Investigational
VinblastineThe metabolism of Vinblastine can be decreased when combined with Desipramine.Approved
VincristineThe excretion of Vincristine can be decreased when combined with Desipramine.Approved, Investigational
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Desipramine.Approved, Investigational
VoriconazoleThe metabolism of Desipramine can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Desipramine.Approved
WarfarinDesipramine may increase the anticoagulant activities of Warfarin.Approved
XimelagatranThe serum concentration of Desipramine can be increased when it is combined with Ximelagatran.Approved, Investigational, Withdrawn
XylometazolineDesipramine may decrease the antihypertensive activities of Xylometazoline.Approved
YohimbineThe serum concentration of Yohimbine can be increased when it is combined with Desipramine.Approved, Vet Approved
Z-Val-Ala-Asp fluoromethyl ketoneThe serum concentration of Desipramine can be increased when it is combined with Z-Val-Ala-Asp fluoromethyl ketone.Experimental
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Desipramine.Approved, Investigational
ZiprasidoneThe metabolism of Desipramine can be decreased when combined with Ziprasidone.Approved
ZofenoprilThe serum concentration of Desipramine can be increased when it is combined with Zofenopril.Experimental
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Desipramine.Approved
ZucapsaicinThe metabolism of Desipramine can be decreased when combined with Zucapsaicin.Approved
ZuclopenthixolThe metabolism of Zuclopenthixol can be decreased when combined with Desipramine.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Take with food to reduce irritation, limit caffeine intake.

References

Synthesis Reference

Biel, J.H.and Judd, C.I.; US. Patent 3,454,554; July 8,1969; assigned to Colgate Palmolive Co.

General References
Not Available
External Links
Human Metabolome Database
HMDB0015282
KEGG Drug
D07791
KEGG Compound
C06943
PubChem Compound
2995
PubChem Substance
46504624
ChemSpider
2888
BindingDB
35229
ChEBI
47781
ChEMBL
CHEMBL72
Therapeutic Targets Database
DAP001151
PharmGKB
PA449233
IUPHAR
2399
Guide to Pharmacology
GtP Drug Page
HET
DSM
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Desipramine
ATC Codes
N06AA01 — Desipramine
AHFS Codes
  • 28:16.04.28 — Tricyclics and Other Norepinephrine-reuptake Inhibitors
PDB Entries
2qb4 / 2qju
FDA label
Download (152 KB)
MSDS
Download (73.6 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers1
1CompletedNot AvailableHealthy Volunteers / Pharmacokinetics of Mirabegron1
1CompletedTreatmentCancers1
1CompletedTreatmentDepression2
1CompletedTreatmentErectile Dysfunction (ED)1
1CompletedTreatmentHealthy Volunteers1
2CompletedTreatmentAlcoholism / Dual Diagnosis / Schizophrenic Disorders1
2CompletedTreatmentBack Pain1
2CompletedTreatmentBack Pain / Sciatica1
2CompletedTreatmentCocaine-Related Disorders1
2CompletedTreatmentCocaine-Related Disorders / Substance-Related Disorders2
2CompletedTreatmentRett's Syndrome1
2CompletedTreatmentSleep Apnea, Obstructive2
2TerminatedTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
3CompletedTreatmentAbdominal Pain (AP) / Functional Colonic Diseases / Irritable Bowel Syndrome (IBS) / Occasional Constipation1
3CompletedTreatmentAlcoholism / Depression / PTSD1
3CompletedTreatmentDepression1
3CompletedTreatmentDepression / Depressive Disorders / Major Depressive Disorder (MDD)1
3CompletedTreatmentGERD1
3CompletedTreatmentHerpes Zoster / Pain1
4CompletedTreatmentDepression1
4CompletedTreatmentMajor Depressive Disorder (MDD)1
4CompletedTreatmentSubstance-Related Disorders1
Not AvailableActive Not RecruitingTreatmentDS Stage I Plasma Cell Myeloma / DS Stage II Plasma Cell Myeloma / DS Stage III Plasma Cell Myeloma / Refractory Plasma Cell Myeloma1
Not AvailableCompletedTreatmentAnxiety Disorders / Depression / Drug-resistant Depression / Personality Disorders1
Not AvailableCompletedTreatmentDepression2
Not AvailableUnknown StatusTreatmentFunctional Dyspepsia1
Not AvailableUnknown StatusTreatmentIrritable Bowel Syndrome (IBS)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
TabletOral10 mg
TabletOral100 mg
TabletOral25 mg
TabletOral50 mg
TabletOral75 mg
TabletOral10 mg/1
TabletOral100 mg/1
TabletOral150 mg/1
TabletOral25 mg/1
TabletOral50 mg/1
TabletOral75 mg/1
Tablet, film coatedOral10 mg/1
Tablet, film coatedOral100 mg/1
Tablet, film coatedOral150 mg/1
Tablet, film coatedOral25 mg/1
Tablet, film coatedOral50 mg/1
Tablet, film coatedOral75 mg/1
Tablet, sugar coatedOral10 mg/1
Tablet, sugar coatedOral100 mg/1
Tablet, sugar coatedOral150 mg/1
Tablet, sugar coatedOral25 mg/1
Tablet, sugar coatedOral50 mg/1
Tablet, sugar coatedOral75 mg/1
Prices
Unit descriptionCostUnit
Desipramine hcl powder14.4USD g
Norpramin 150 mg tablet6.08USD tablet
Desipramine HCl 150 mg tablet4.67USD tablet
Norpramin 100 mg tablet4.2USD tablet
Norpramin 75 mg tablet3.19USD tablet
Desipramine HCl 100 mg tablet2.81USD tablet
Desipramine HCl 75 mg tablet2.63USD tablet
Norpramin 50 mg tablet2.51USD tablet
Desipramine 150 mg tablet2.18USD tablet
Desipramine HCl 50 mg tablet1.64USD tablet
Desipramine 100 mg tablet1.5USD tablet
Norpramin 25 mg tablet1.33USD tablet
Desipramine 75 mg tablet1.15USD tablet
Norpramin 10 mg tablet1.11USD tablet
Apo-Desipramine 75 mg Tablet0.93USD tablet
Desipramine 50 mg tablet0.92USD tablet
Desipramine HCl 10 mg tablet0.87USD tablet
Desipramine HCl 25 mg tablet0.83USD tablet
Apo-Desipramine 50 mg Tablet0.7USD tablet
Desipramine 25 mg tablet0.49USD tablet
Desipramine 10 mg tablet0.4USD tablet
Apo-Desipramine 10 mg Tablet0.4USD tablet
Apo-Desipramine 25 mg Tablet0.4USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)214-218 °CNot Available
water solubility58.6 mg/L (at 24 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP4.90HANSCH,C ET AL. (1995)
logS-3.66ADME Research, USCD
Caco2 permeability-4.67ADME Research, USCD
pKa10.4SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.0396 mg/mLALOGPS
logP4.02ALOGPS
logP3.9ChemAxon
logS-3.8ALOGPS
pKa (Strongest Basic)10.02ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area15.27 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity85.31 m3·mol-1ChemAxon
Polarizability31.74 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9958
Blood Brain Barrier+0.9854
Caco-2 permeable+0.8868
P-glycoprotein substrateSubstrate0.7945
P-glycoprotein inhibitor IInhibitor0.8564
P-glycoprotein inhibitor IINon-inhibitor0.6353
Renal organic cation transporterInhibitor0.7955
CYP450 2C9 substrateNon-substrate0.7684
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateNon-substrate0.5117
CYP450 1A2 substrateInhibitor0.9029
CYP450 2C9 inhibitorNon-inhibitor0.9125
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorNon-inhibitor0.9241
CYP450 3A4 inhibitorInhibitor0.744
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8478
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.9476
BiodegradationNot ready biodegradable0.9686
Rat acute toxicity2.8197 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8569
hERG inhibition (predictor II)Inhibitor0.8604
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (11 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-0544-7980000000-e155fe1ae5cd0aa22da3
Mass Spectrum (Electron Ionization)MSsplash10-0006-4970000000-810535cb33c37107abc5
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as dibenzazepines. These are compounds with two benzene rings connected by an azepine ring. Azepine is an unsaturated seven-member heterocycle with one nitrogen atom replacing a carbon atom.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzazepines
Sub Class
Dibenzazepines
Direct Parent
Dibenzazepines
Alternative Parents
Alkyldiarylamines / Azepines / Benzenoids / Dialkylamines / Azacyclic compounds / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Dibenzazepine / Alkyldiarylamine / Tertiary aliphatic/aromatic amine / Azepine / Benzenoid / Tertiary amine / Azacycle / Secondary amine / Secondary aliphatic amine / Organic nitrogen compound
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
secondary amino compound, dibenzoazepine (CHEBI:47781)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Norepinephrine:sodium symporter activity
Specific Function
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name
SLC6A2
Uniprot ID
P23975
Uniprot Name
Sodium-dependent noradrenaline transporter
Molecular Weight
69331.42 Da
References
  1. Zavosh A, Schaefer J, Ferrel A, Figlewicz DP: Desipramine treatment decreases 3H-nisoxetine binding and norepinephrine transporter mRNA in SK-N-SHSY5Y cells. Brain Res Bull. 1999 Jul 1;49(4):291-5. [PubMed:10424850]
  2. Weinshenker D, White SS, Javors MA, Palmiter RD, Szot P: Regulation of norepinephrine transporter abundance by catecholamines and desipramine in vivo. Brain Res. 2002 Aug 16;946(2):239-46. [PubMed:12137927]
  3. Bryan-Lluka LJ, Bonisch H, Lewis RJ: chi-Conopeptide MrIA partially overlaps desipramine and cocaine binding sites on the human norepinephrine transporter. J Biol Chem. 2003 Oct 10;278(41):40324-9. Epub 2003 Jul 1. [PubMed:12837768]
  4. Zhu MY, Kyle PB, Hume AS, Ordway GA: The persistent membrane retention of desipramine causes lasting inhibition of norepinephrine transporter function. Neurochem Res. 2004 Feb;29(2):419-27. [PubMed:15002740]
  5. Ordway GA, Jia W, Li J, Zhu MY, Mandela P, Pan J: Norepinephrine transporter function and desipramine: residual drug effects versus short-term regulation. J Neurosci Methods. 2005 Apr 30;143(2):217-25. Epub 2004 Dec 30. [PubMed:15814154]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  7. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serotonin:sodium symporter activity
Specific Function
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into t...
Gene Name
SLC6A4
Uniprot ID
P31645
Uniprot Name
Sodium-dependent serotonin transporter
Molecular Weight
70324.165 Da
References
  1. Holmes A, Yang RJ, Murphy DL, Crawley JN: Evaluation of antidepressant-related behavioral responses in mice lacking the serotonin transporter. Neuropsychopharmacology. 2002 Dec;27(6):914-23. [PubMed:12464448]
  2. Gould GG, Altamirano AV, Javors MA, Frazer A: A comparison of the chronic treatment effects of venlafaxine and other antidepressants on serotonin and norepinephrine transporters. Biol Psychiatry. 2006 Mar 1;59(5):408-14. Epub 2005 Sep 2. [PubMed:16140280]
  3. Zhou L, Huang KX, Kecojevic A, Welsh AM, Koliatsos VE: Evidence that serotonin reuptake modulators increase the density of serotonin innervation in the forebrain. J Neurochem. 2006 Jan;96(2):396-406. Epub 2005 Nov 21. [PubMed:16300628]
  4. Hoffman AF, Gerhardt GA: In vivo electrochemical studies of dopamine clearance in the rat substantia nigra: effects of locally applied uptake inhibitors and unilateral 6-hydroxydopamine lesions. J Neurochem. 1998 Jan;70(1):179-89. [PubMed:9422361]
  5. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein homodimerization activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately ...
Gene Name
ADRB2
Uniprot ID
P07550
Uniprot Name
Beta-2 adrenergic receptor
Molecular Weight
46458.32 Da
References
  1. Matsumoto K, Ojima K, Ohta H, Watanabe H: Beta 2- but not beta 1-adrenoceptors are involved in desipramine enhancement of aggressive behavior in long-term isolated mice. Pharmacol Biochem Behav. 1994 Sep;49(1):13-8. [PubMed:7816863]
  2. Sapena R, Morin D, Zini R, Morin C, Tillement JP: Desipramine treatment differently down-regulates beta-adrenoceptors of freshly isolated neurons and astrocytes. Eur J Pharmacol. 1996 Apr 4;300(1-2):159-62. [PubMed:8741184]
  3. Abadie C, Foucart S, Page P, Nadeau R: Modulation of noradrenaline release from isolated human atrial appendages. J Auton Nerv Syst. 1996 Dec 14;61(3):269-76. [PubMed:8988485]
  4. Prenner L, Sieben A, Zeller K, Weiser D, Haberlein H: Reduction of high-affinity beta2-adrenergic receptor binding by hyperforin and hyperoside on rat C6 glioblastoma cells measured by fluorescence correlation spectroscopy. Biochemistry. 2007 May 1;46(17):5106-13. Epub 2007 Apr 7. [PubMed:17417877]
  5. Osadchii OE, Woodiwiss AJ, Deftereos D, Norton GR: Temporal changes in myocardial adrenergic regulation with the progression to pump dysfunction after chronic beta-adrenoreceptor activation in rats. Pflugers Arch. 2007 Nov;455(2):251-60. Epub 2007 Jun 9. [PubMed:17558518]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other
General Function
Receptor signaling protein activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately e...
Gene Name
ADRB1
Uniprot ID
P08588
Uniprot Name
Beta-1 adrenergic receptor
Molecular Weight
51322.1 Da
References
  1. Sapena R, Morin D, Zini R, Morin C, Tillement JP: Desipramine treatment differently down-regulates beta-adrenoceptors of freshly isolated neurons and astrocytes. Eur J Pharmacol. 1996 Apr 4;300(1-2):159-62. [PubMed:8741184]
  2. Burgi S, Baltensperger K, Honegger UE: Antidepressant-induced switch of beta 1-adrenoceptor trafficking as a mechanism for drug action. J Biol Chem. 2003 Jan 10;278(2):1044-52. Epub 2002 Oct 21. [PubMed:12393876]
  3. Matsumoto K, Ojima K, Ohta H, Watanabe H: Beta 2- but not beta 1-adrenoceptors are involved in desipramine enhancement of aggressive behavior in long-term isolated mice. Pharmacol Biochem Behav. 1994 Sep;49(1):13-8. [PubMed:7816863]
  4. Samnick S, Scheuer C, Munks S, El-Gibaly AM, Menger MD, Kirsch CM: Technetium-99m labeled 1-(4-fluorobenzyl)-4-(2-mercapto-2-methyl-4-azapentyl)-4-(2-mercapto-2-methylprop ylamino)-piperidine and iodine-123 metaiodobenzylguanidine for studying cardiac adrenergic function: a comparison of the uptake characteristics in vascular smooth muscle cells and neonatal cardiac myocytes, and an investigation in rats. Nucl Med Biol. 2004 May;31(4):511-22. [PubMed:15093822]
  5. Mudunkotuwa NT, Horton RW: Desipramine administration in the olfactory bulbectomized rat: changes in brain beta-adrenoceptor and 5-HT2A binding sites and their relationship to behaviour. Br J Pharmacol. 1996 Apr;117(7):1481-6. [PubMed:8730743]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sphingomyelin phosphodiesterase activity
Specific Function
Converts sphingomyelin to ceramide. Also has phospholipase C activities toward 1,2-diacylglycerolphosphocholine and 1,2-diacylglycerolphosphoglycerol. Isoform 2 and isoform 3 have lost catalytic ac...
Gene Name
SMPD1
Uniprot ID
P17405
Uniprot Name
Sphingomyelin phosphodiesterase
Molecular Weight
69751.3 Da
References
  1. Testai FD, Landek MA, Dawson G: Regulation of sphingomyelinases in cells of the oligodendrocyte lineage. J Neurosci Res. 2004 Jan 1;75(1):66-74. [PubMed:14689449]
  2. Kolzer M, Werth N, Sandhoff K: Interactions of acid sphingomyelinase and lipid bilayers in the presence of the tricyclic antidepressant desipramine. FEBS Lett. 2004 Feb 13;559(1-3):96-8. [PubMed:14960314]
  3. Erdreich-Epstein A, Tran LB, Cox OT, Huang EY, Laug WE, Shimada H, Millard M: Endothelial apoptosis induced by inhibition of integrins alphavbeta3 and alphavbeta5 involves ceramide metabolic pathways. Blood. 2005 Jun 1;105(11):4353-61. Epub 2005 Feb 10. [PubMed:15705795]
  4. Zeidan YH, Pettus BJ, Elojeimy S, Taha T, Obeid LM, Kawamori T, Norris JS, Hannun YA: Acid ceramidase but not acid sphingomyelinase is required for tumor necrosis factor-{alpha}-induced PGE2 production. J Biol Chem. 2006 Aug 25;281(34):24695-703. Epub 2006 Jun 27. [PubMed:16803890]
  5. Hurwitz R, Ferlinz K, Sandhoff K: The tricyclic antidepressant desipramine causes proteolytic degradation of lysosomal sphingomyelinase in human fibroblasts. Biol Chem Hoppe Seyler. 1994 Jul;375(7):447-50. [PubMed:7945993]
  6. Kornhuber J, Tripal P, Reichel M, Muhle C, Rhein C, Muehlbacher M, Groemer TW, Gulbins E: Functional Inhibitors of Acid Sphingomyelinase (FIASMAs): a novel pharmacological group of drugs with broad clinical applications. Cell Physiol Biochem. 2010;26(1):9-20. doi: 10.1159/000315101. Epub 2010 May 18. [PubMed:20502000]
Details
7. Histamine H1 receptor
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da
References
  1. Sawynok J, Esser MJ, Reid AR: Peripheral antinociceptive actions of desipramine and fluoxetine in an inflammatory and neuropathic pain test in the rat. Pain. 1999 Aug;82(2):149-58. [PubMed:10467920]
  2. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]
Kind
Protein group
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...

Components:
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM1
Uniprot ID
P11229
Uniprot Name
Muscarinic acetylcholine receptor M1
Molecular Weight
51420.375 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]
  2. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  3. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
G-protein coupled acetylcholine receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM2
Uniprot ID
P08172
Uniprot Name
Muscarinic acetylcholine receptor M2
Molecular Weight
51714.605 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]
  2. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  3. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
Receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM3
Uniprot ID
P20309
Uniprot Name
Muscarinic acetylcholine receptor M3
Molecular Weight
66127.445 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
Guanyl-nucleotide exchange factor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM4
Uniprot ID
P08173
Uniprot Name
Muscarinic acetylcholine receptor M4
Molecular Weight
53048.65 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM5
Uniprot ID
P08912
Uniprot Name
Muscarinic acetylcholine receptor M5
Molecular Weight
60073.205 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers...
Gene Name
HTR1A
Uniprot ID
P08908
Uniprot Name
5-hydroxytryptamine receptor 1A
Molecular Weight
46106.335 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-...
Gene Name
HTR2C
Uniprot ID
P28335
Uniprot Name
5-hydroxytryptamine receptor 2C
Molecular Weight
51820.705 Da
References
  1. Palvimaki EP, Roth BL, Majasuo H, Laakso A, Kuoppamaki M, Syvalahti E, Hietala J: Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c receptor. Psychopharmacology (Berl). 1996 Aug;126(3):234-40. [PubMed:8876023]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]
Kind
Protein group
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Thioesterase binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...

Components:
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Baumann P: Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1996 Dec;31(6):444-69. [PubMed:8968657]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Lewis DF, Modi S, Dickins M: Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82. [PubMed:11996013]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C18
Uniprot ID
P33260
Uniprot Name
Cytochrome P450 2C18
Molecular Weight
55710.075 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Const...
Gene Name
CYP2A6
Uniprot ID
P11509
Uniprot Name
Cytochrome P450 2A6
Molecular Weight
56501.005 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
Molecular Weight
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
Gene Name
CYP2E1
Uniprot ID
P05181
Uniprot Name
Cytochrome P450 2E1
Molecular Weight
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
No
General Function
Not Available
Specific Function
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in...
Gene Name
ORM1
Uniprot ID
P02763
Uniprot Name
Alpha-1-acid glycoprotein 1
Molecular Weight
23511.38 Da
References
  1. Ferry DG, Caplan NB, Cubeddu LX: Interaction between antidepressants and alpha 1-adrenergic receptor antagonists on the binding to alpha 1-acid glycoprotein. J Pharm Sci. 1986 Feb;75(2):146-9. [PubMed:2870173]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37. [PubMed:12438524]
  2. Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9. [PubMed:14985103]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Secondary active organic cation transmembrane transporter activity
Specific Function
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnico...
Gene Name
SLC22A1
Uniprot ID
O15245
Uniprot Name
Solute carrier family 22 member 1
Molecular Weight
61153.345 Da
References
  1. Zhang L, Schaner ME, Giacomini KM: Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa). J Pharmacol Exp Ther. 1998 Jul;286(1):354-61. [PubMed:9655880]
  2. Arndt P, Volk C, Gorboulev V, Budiman T, Popp C, Ulzheimer-Teuber I, Akhoundova A, Koppatz S, Bamberg E, Nagel G, Koepsell H: Interaction of cations, anions, and weak base quinine with rat renal cation transporter rOCT2 compared with rOCT1. Am J Physiol Renal Physiol. 2001 Sep;281(3):F454-68. [PubMed:11502595]
  3. Grundemann D, Gorboulev V, Gambaryan S, Veyhl M, Koepsell H: Drug excretion mediated by a new prototype of polyspecific transporter. Nature. 1994 Dec 8;372(6506):549-52. [PubMed:7990927]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Quaternary ammonium group transmembrane transporter activity
Specific Function
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creat...
Gene Name
SLC22A2
Uniprot ID
O15244
Uniprot Name
Solute carrier family 22 member 2
Molecular Weight
62579.99 Da
References
  1. Gorboulev V, Ulzheimer JC, Akhoundova A, Ulzheimer-Teuber I, Karbach U, Quester S, Baumann C, Lang F, Busch AE, Koepsell H: Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol. 1997 Jul;16(7):871-81. [PubMed:9260930]
  2. Arndt P, Volk C, Gorboulev V, Budiman T, Popp C, Ulzheimer-Teuber I, Akhoundova A, Koppatz S, Bamberg E, Nagel G, Koepsell H: Interaction of cations, anions, and weak base quinine with rat renal cation transporter rOCT2 compared with rOCT1. Am J Physiol Renal Physiol. 2001 Sep;281(3):F454-68. [PubMed:11502595]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Toxin transporter activity
Specific Function
Mediates potential-dependent transport of a variety of organic cations. May play a significant role in the disposition of cationic neurotoxins and neurotransmitters in the brain.
Gene Name
SLC22A3
Uniprot ID
O75751
Uniprot Name
Solute carrier family 22 member 3
Molecular Weight
61279.485 Da
References
  1. Wu X, Huang W, Ganapathy ME, Wang H, Kekuda R, Conway SJ, Leibach FH, Ganapathy V: Structure, function, and regional distribution of the organic cation transporter OCT3 in the kidney. Am J Physiol Renal Physiol. 2000 Sep;279(3):F449-58. [PubMed:10966924]
  2. Kekuda R, Prasad PD, Wu X, Wang H, Fei YJ, Leibach FH, Ganapathy V: Cloning and functional characterization of a potential-sensitive, polyspecific organic cation transporter (OCT3) most abundantly expressed in placenta. J Biol Chem. 1998 Jun 26;273(26):15971-9. [PubMed:9632645]
  3. Wu X, Kekuda R, Huang W, Fei YJ, Leibach FH, Chen J, Conway SJ, Ganapathy V: Identity of the organic cation transporter OCT3 as the extraneuronal monoamine transporter (uptake2) and evidence for the expression of the transporter in the brain. J Biol Chem. 1998 Dec 4;273(49):32776-86. [PubMed:9830022]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Symporter activity
Specific Function
Sodium-ion dependent, high affinity carnitine transporter. Involved in the active cellular uptake of carnitine. Transports one sodium ion with one molecule of carnitine. Also transports organic cat...
Gene Name
SLC22A5
Uniprot ID
O76082
Uniprot Name
Solute carrier family 22 member 5
Molecular Weight
62751.08 Da
References
  1. Wu X, Huang W, Prasad PD, Seth P, Rajan DP, Leibach FH, Chen J, Conway SJ, Ganapathy V: Functional characteristics and tissue distribution pattern of organic cation transporter 2 (OCTN2), an organic cation/carnitine transporter. J Pharmacol Exp Ther. 1999 Sep;290(3):1482-92. [PubMed:10454528]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Symporter activity
Specific Function
Sodium-ion dependent, low affinity carnitine transporter. Probably transports one sodium ion with one molecule of carnitine. Also transports organic cations such as tetraethylammonium (TEA) without...
Gene Name
SLC22A4
Uniprot ID
Q9H015
Uniprot Name
Solute carrier family 22 member 4
Molecular Weight
62154.48 Da
References
  1. Wu X, George RL, Huang W, Wang H, Conway SJ, Leibach FH, Ganapathy V: Structural and functional characteristics and tissue distribution pattern of rat OCTN1, an organic cation transporter, cloned from placenta. Biochim Biophys Acta. 2000 Jun 1;1466(1-2):315-27. [PubMed:10825452]

Drug created on June 13, 2005 07:24 / Updated on January 19, 2018 10:54